We have located links that may give you full text access.
Journal Article
Review
How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Best Practice & Research. Clinical Haematology 2017 September
Treatment of older patients with Philadelphia-chromosome-positive (Ph+) acute lymphoblastic leukemia presents unique challenges. Advanced age, comorbidities, high treatment-related death rates with traditional chemotherapy, and relapse combine to yield poor survival. Reduced-intensity induction with BCR-ABL1 targeted tyrosine kinase inhibitors (TKIs) and corticosteroids yields CR rates 96-100% with no induction mortality but relapse is nearly certain without effective consolidation. Few clinical trials provide guidance on optimal consolidation for older Ph+ ALL. With second-generation TKIs, lower intensity chemotherapy after induction gives similar outcomes to intensive consolidation although long-term survival is still poor. Consolidation with allogeneic or autologous hematopoietic cell transplantation may improve survival for fit older patients. Novel targeted therapies like blinatumomab, inotuzumab ozogamicin, and CD19-targeted CAR T-cells hold promise to improve survival with reduced toxicity. Better understanding these approaches will require increased referral to specialized centers, expansion of clinical trials, and improved enrollment of older ALL patients on trials.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app